Could a new oral ketamine capsule ease bipolar depression when other treatments fail?
Symptom relief
Not yet recruiting
This study tests an oral ketamine capsule (KET-AD) designed to be abuse-deterrent in adults with treatment-resistant bipolar depression. About 160 participants will receive either KET-AD or a placebo, taken three times a week for up to 7 weeks, alongside their usual treatment. Th…
Phase: PHASE2 • Sponsor: Neurocentrx Pharma Pty Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC